PMDA drug package insert
リスペリドンOD錠0.5mg「タカタ」
PMDA Prescription drug · 高田製薬株式会社 · package insert Oct 29, 2024
Key facts
| Brand names | リスペリドンOD錠0.5mg「タカタ」, リスペリドンOD錠1mg「タカタ」, リスペリドンOD錠2mg「タカタ」, リスペリドンOD錠3mg「タカタ」 |
|---|---|
| Nonproprietary names | リスペリドン |
| Companies | 製造販売元／高田製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗精神病剤 |
| Therapeutic category codes | 871179 |
| YJ codes | 1179038F7030, 1179038F5053, 1179038F6050, 1179038F8028 |
| Approval numbers | 22300AMX00945, 22100AMX02103, 22100AMX02104, 22100AMX02105 |
| Package insert edition | 第2版 |
| Package insert date | Oct 29, 2024 |
| PMDA document key | 400186_1179038F5053_1 |
| PMDA company code | 400186 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: